Evidence map›Paper›PMID 38463578›Full record

ArticleAmerican journal of translational research2024

CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology.

Hanjie Hu, Muhammad Umair, Sikandar Ali Khan, Aliya Irshad Sani, Sahar Iqbal, Fatima Khalid, Rizwana Sultan, Mostafa A Abdel-Maksoud, Ayman Mubarak, Turki M Dawoud and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. [Research Progress of TNMB Staging in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Hanjie HuDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021, China.
Muhammad UmairDepartment of Physiology, Gomal Medical College, MTI Dera Ismail Khan, Pakistan.
Sikandar Ali KhanDepartment of Biochemistry Khyber Girls Medical College Peshawar, Pakistan.
Aliya Irshad SaniDepartment of Biochemistry, Ziauddin Medical College Karachi 74700, Pakistan.
Sahar IqbalDepartment of Pathology, Azra Naheed Medical College Lahore 54000, Pakistan.
Fatima KhalidDepartment of Pathology, Al Aleem Medical College Lahore, Pakistan.
Rizwana SultanDepartment of Pathology, Faculty of Veterinary and Animal Sciences, Cholistan University of Veterinary and Animal Sciences Bahawalpur, Pakistan.
Mostafa A Abdel-MaksoudDepartment of Botany and Microbiology, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Ayman MubarakDepartment of Botany and Microbiology, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Turki M DawoudDepartment of Botany and Microbiology, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Abdul MalikDepartment of Pharmaceutics, College of Pharmacy, King Saud University Saudi Arabia.
Ibrahim A SalehFaculty of Science, Zarqa University Zarqa 13110, Jordan.
Abdul Aziz Al AmriBiochemistry Department, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Norah Khaled AlgarzaeDepartment of Physiology, College of Medicine, King Saud University Riyadh 11149, Saudi Arabia.
Ahmad S KodousRadiation Biology Department, National Center for Radiation Research & Technology (NCRRT), Egyptian Atomic-Energy Authority (EAEA) Egypt.
Yasir HameedDepartment of Biotechnology, Institute of Biochemistry Biotechnology and Bioinformatics, The Islamia University of Bahawalpur Bahawalpur 63100, Pakistan.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman cell division cycle-associated protein 8 (CDCA8), a critical regulator of mitosis, has been identified as a prospective prognostic biomarker in several cancer types, including breast, colon, and lung cancers. This study analyzed the diagnostic/prognostic potential and clinical implications of CDCA8 across diverse cancers.

methodsBioinformatics and molecular experiments.

resultsAnalyzing TCGA data via TIMER2 and GEPIA2 databases revealed significant up-regulation of CDCA8 in 23 cancer types compared to normal tissues. Prognostically, elevated CDCA8 expression correlated with poorer overall survival in KIRC, LUAD, and SKCM, emphasizing its potential as a prognostic marker. UALCAN analysis demonstrated CDCA8 up-regulation based on clinical variables, such as cancer stage, race, and gender, in these cancers. Epigenetic exploration indicated reduced CDCA8 promoter methylation levels in Kidney Renal Clear Cell Carcinoma (KIRC), Lung Adenocarcinoma (LUAD), and Skin Cutaneous Melanoma (SKCM) tissues compared to normal controls. Promoter methylation and mutational analyses showcased a hypomethylation and low mutation rate for CDCA8 in these cancers. Correlation analysis revealed positive associations between CDCA8 expression and infiltrating immune cells, particularly CD8+ and CD4+ T cells. Protein-protein interaction (PPI) network analysis unveiled key interacting proteins, while gene enrichment analysis highlighted their involvement in crucial cellular processes and pathways. Additionally, exploration of CDCA8-associated drugs through DrugBank presented potential therapeutic options for KIRC, LUAD, and SKCM. In vitro validation using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) confirmed elevated CDCA8 expression in LUAD cell lines (A549 and H1299) compared to control cell lines (Beas-2B and NL-20).

conclusionThis study provides concise insights into CDCA8's multifaceted role in KIRC, LUAD, and SKCM, covering expression patterns, diagnostic and prognostic relevance, epigenetic regulation, mutational landscape, immune infiltration, and therapeutic implications.

Indexed as

biomarkerCDCA8pan-cancerprognosistreatment

Identifiers

PMID38463578
PMCPMC10918119
OpenAlexW4393045548

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.